In order to increase domestic production capacity, all seven remdesivir producers in the country have been asked to step up production quickly, the ministry said in a statement.
The production capacity of remdesivir used to treat COVID-19 has increased from 38 bottles per month to almost 1.19 crore bottles per month, the Ministry of Chemicals and Fertilizers announced on Monday. Remdesivir is manufactured in India under voluntary licenses granted by Gilead Life Sciences to 7 pharmaceutical companies – Cipla, Dr Reddy’s, Hetero, Jubilant Pharma, Mylan, Syngene and Zydus Cadila, she added.
In order to increase domestic production capacity, all seven remdesivir producers in the country have been asked to boost production quickly, the ministry said in a statement.
“Through the combined efforts of the central government and manufacturing companies, the production capacity of licensed manufacturers has increased unprecedentedly from 38 bottles of salmon per month to almost 119 bottles of salmon per month,” it adds.
With the accelerated approval of 38 additional production sites, the number of approved remdesivir production sites in the country has increased from 22 to 60 sites, the statement said.
With the help of the Ministry of Foreign Affairs, it is easier for remdesivir producers to procure the necessary raw materials and equipment from foreign countries, he noted.
Every effort is being made to increase the availability of the drug through imports, as well as increased domestic production, the ministry said.
The export of remesivers has been banned since April 11, 2021. Customs is exempt from injections of remdesivir, API remdesivir and beta cyclodextrins used in the production of remdesivir, and enters into force on April 20, 2021.
Also read: The serum must reimburse the supply of vaccines against COVID-19 and the obligation to supply COVAX: WHO